COVID-19 pandemic in Japan

被引：0
作者：
Olga Amengual
Tatsuya Atsumi
机构：
[1] Hokkaido University,Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine
来源：
Rheumatology International | 2021年 / 41卷
关键词：
COVID-19; Pandemic; Japan; SARS-CoV-2;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Coronavirus Disease-2019 (COVID-19), is a global emergency. The first case of COVID-19 was confirmed in Japan in January 2020, a second outbreak of infection occurred in mid-March and a third peak at the beginning of August. The COVID-19 phenotype was milder in Japan than in other countries, although the restrictive measures applied in the country have not been as strict as in other places. Factors related to a possible reduced susceptibility to the pulmonary manifestations of SARS-CoV-2 may have contributed to better outcomes and lower mortality in Japan.
引用
收藏
页码：1 / 5
页数：4
相关论文
共 89 条
[1]  
Sawalha AH(2020)Coronavirus Disease-2019: Implication for the care and management of patients with systemic lupus erythematosus Eur J Rheumatol 7 S117-S120
[2]  
Manzi S(2020)Why does Japan have so few cases of COVID-19? EMBO Mol Med 12 e12481-834
[3]  
Iwasaki A(2020)Coronaviruses and immunosuppressed patients: the facts during the third epidemic Liver Transpl 26 832-241
[4]  
Grubaugh ND(2020)Exacerbation of immune thrombocytopaenia triggered by COVID-19 in patients with systemic lupus erythematosus Ann Rheum Dis 26 240-1595
[5]  
D'Antiga L(2020)COVID-19 in a patient with rheumatoid arthritis during tocilizumab treatment J Clin Rheumatol 47 1593-722
[6]  
Kondo Y(2020)Angiotensin-converting enzyme 2, a SARS-CoV-2 receptor, is upregulated by interleukin 6 through STAT3 signaling in synovial tissues J Rheumatol 23 717-1505
[7]  
Kaneko Y(2020)Care for patients with rheumatic diseases during COVID-19 pandemic: a position statement from APLAR Int J Rheum Dis 39 1499-68
[8]  
Oshige T(2019)Rheumatology practice in Japan: challenges and opportunities Rheumatol Int 73 62-1104
[9]  
Fukui H(2014)Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA) Ann Rheum Dis 43 1103-1204
[10]  
Saito S(2004)Interstitial lung disease associated with leflunomide Intern Med 43 1201-1072
123456789